Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells
- 1 January 1998
- journal article
- Published by Elsevier in Atherosclerosis
- Vol. 136 (1) , 163-168
- https://doi.org/10.1016/s0021-9150(97)00207-4
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.Journal of Clinical Investigation, 1996
- The new oral hypoglycemic agent, CS-045, inhibits the lipid peroxidation of human plasma low density lipoprotein in vitroBiochemical Pharmacology, 1995
- Role of GTP-binding proteins in the polyunsaturated fatty acid stimulated proliferation of mouse mammary epithelial cellsProstaglandins, Leukotrienes & Essential Fatty Acids, 1995
- Thiazolidine Derivatives Ameliorate High Glucose-induced Insulin Resistance via the Normalization of Protein-tyrosine Phosphatase ActivitiesJournal of Biological Chemistry, 1995
- Insulin-specific activation of S6 kinase and its desensitization in cultured rat vascular smooth muscle cellsAtherosclerosis, 1995
- Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with TroglitazoneNew England Journal of Medicine, 1994
- Regulation of glucose transport by pioglitazone in cultured muscle cellsMetabolism, 1994
- Regulation of gene transcription by polyunsaturated fatty acidsProgress in Lipid Research, 1993
- Pathogenesis of NIDDM: A Balanced OverviewDiabetes Care, 1992
- Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM SubjectsDiabetes Care, 1992